Nanjing Gaoke Company Limited

Shanghai Stock Exchange 600064.SS

Nanjing Gaoke Company Limited Return on Equity (ROE) for the year ending December 31, 2023: 8.90%

Nanjing Gaoke Company Limited Return on Equity (ROE) is 8.90% for the year ending December 31, 2023, a -38.67% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Nanjing Gaoke Company Limited Return on Equity (ROE) for the year ending December 31, 2022 was 14.50%, a -7.06% change year over year.
Nanjing Gaoke Company Limited Return on Equity (ROE) for the year ending December 31, 2021 was 15.61%, a 2.62% change year over year.
Nanjing Gaoke Company Limited Return on Equity (ROE) for the year ending December 31, 2020 was 15.21%, a -2.43% change year over year.
Nanjing Gaoke Company Limited Return on Equity (ROE) for the year ending December 31, 2019 was 15.59%, a 51.76% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Shanghai Stock Exchange: 600064.SS

Nanjing Gaoke Company Limited

CEO	Mr. Yang Jun Lu
IPO Date	May 6, 1997
Location	China
Headquarters	Hi-Tech Center
Employees	508
Sector	Industrials
Industries Construction Homebuilding

Description

Nanjing Gaoke Company Limited develops real estate properties in China. The company develops and sells commercial residential properties; and undertakes renovation of old communities, new roads, and mountain park construction projects. It also offers house construction, municipal engineering construction and supervision, landscaping construction and maintenance, sewage treatment, and water supply services; and property management, land development, engineering design, and environmental protection project construction services. In addition, the company is involved in the industrial investment, venture capital, securities, investment management, consulting, and other investment activities; and provision of financing services for small and medium-sized technology companies, and start entrepreneurship. Further, it engages in the production and sale of various Chinese and Western medicine preparations; medical and health care consulting and service activities; and provision of leasing houses. The company was founded in 1992 and is based in Nanjing, China.

Key trends

Past 5 years